Passage Bio, Inc. — Form 8-K Summary
Business Context and Reporting Period
Passage Bio, Inc. filed a Current Report on Form 8-K dated May 21, 2024, under Item 5.07, reporting the results of its 2024 Annual Meeting of Stockholders. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol PASG.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial results.
Material Changes Versus the Prior Comparable Period
- Stockholders elected William Chou, M.D. and Derrell Porter, M.D. as Class I directors for three-year terms expiring at the 2027 Annual Meeting, subject to earlier resignation or removal.
- Stockholders ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management commentary, risk updates, contingencies, or unusual financial items. The reported matters are corporate-governance actions.
Important Facts to Verify
- William Chou, M.D.: 35,909,628 votes for, 786,951 withheld, and 10,034,554 broker non-votes.
- Derrell Porter, M.D.: 27,072,576 votes for, 9,624,003 withheld, and 10,034,554 broker non-votes.
- KPMG LLP ratification: 45,565,348 votes for, 1,104,311 against, and 61,474 abstentions; there were no broker non-votes.
- The filing date is May 21, 2024; the report was signed on May 22, 2024, by Kathleen Borthwick, Chief Financial Officer.